A Non-Interventional Interview Study of Phenylketonuria (PKU) Adults (165-901)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03505125 |
Recruitment Status :
Completed
First Posted : April 23, 2018
Last Update Posted : January 14, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Phenylketonuria (PKU) |
Study Type : | Observational |
Actual Enrollment : | 63 participants |
Observational Model: | Other |
Time Perspective: | Retrospective |
Official Title: | A Non-Interventional Observational Study of Pegvaliase-Naïve Adults With Phenylketonuria (PKU): Concept Elicitation and Cognitive Interviews |
Actual Study Start Date : | March 31, 2018 |
Actual Primary Completion Date : | July 31, 2019 |
Actual Study Completion Date : | July 31, 2019 |
Group/Cohort |
---|
PKU Patients
Adults with PKU will be interviewed about the symptoms and impacts of PKU.
|
Observers
Close friends and family members of adults with PKU will be interviewed about the behaviors they have observed in adults with PKU
|
Clinical Experts
Experienced, practicing clinicians currently treating adults with PKU will be interviewed about the symptoms and impacts of PKU on their patients.
|
- PKU Symptom Survey [ Time Frame: 15 minutes ]60 item survey asking patients, observers and clinical experts about the symptoms and behaviors associated with PKU and changes in Phe level.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
- Individuals with PKU ≥18 years to ≤ 70 years of age who are naïve to pegvaliase
- Observers ≥18 years of an individual with PKU ≥18 years to ≤ 70 years of age who are naïve to pegvaliase
- Clinical experts currently treating PKU adults
Inclusion Criteria:
Patients eligible to participate in this study must meet all of the following criteria:
- ≥18 and ≤70 years of age at the time of consent;
- Clinically-confirmed diagnosis of Phenylketonuria (PKU);
- Blood Phe test completed within eight weeks prior to screening date or blood Phe test completed within eight weeks post screening date;
- Able to read, understand, and speak fluently the language(s) of their designated country sufficiently to participate in an interview and/or complete all assessments;
- Willing and able to participate in a telephone interview lasting approximately 90 minutes;
- Willing to be audio-recorded during the interview session;
- Willing and able to provide written informed consent indicating that they understand the purpose and procedures required for the study and are willing to participate.
Exclusion Criteria:
Patients meeting any of the following criteria will not be included in the study:
- Currently pregnant;
- Current or previous exposure to pegvaliase treatment or participation in a pegvaliase clinical trial;
- Has a significant cognitive impairment, hearing difficulty, visual impairment, acute psychopathology, medical condition, or insufficient knowledge of the interview language that, in the opinion of the investigator or interviewer, would interfere with his or her ability to provide written consent and participate/complete an interview.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03505125
United States, Florida | |
University of Florida | |
Gainesville, Florida, United States, 32610 | |
United States, Georgia | |
Emory University Department of Human Genetics | |
Decatur, Georgia, United States, 30033 | |
United States, Illinois | |
Ann and Robert H Lurie Children's Hospital | |
Chicago, Illinois, United States, 60614 | |
United States, Massachusetts | |
Boston Children's Hospital | |
Boston, Massachusetts, United States, 02115 | |
Canada, British Columbia | |
Adult Metabolic Diseases Clinic, Vancouver General Hospital | |
Vancouver, British Columbia, Canada | |
France | |
Necker Children's Hospital | |
Paris, Cedex 15, France, 75743 | |
Bretonneau Hospital, Internal Medicine Department | |
Tours, Cedex 9, France, 37044 | |
Germany | |
University Klinik Jena, Klinik für Neuropädiatrie | |
Jena, Thuringia, Germany | |
Rheumatology Unit, Clinic for Inborn Errors of Metabolism | |
Leipzig, Germany | |
Italy | |
Hospital of Padova | |
Padova, Italy, 35128 | |
Umberto I Polyclinic of Rome | |
Roma, Italy, 00185 | |
Turkey | |
Hacettepe University | |
Ankara, Turkey | |
Ege University School of Medicine | |
İzmir, Turkey, 35040 | |
United Kingdom | |
National Hospital for Neurology and Neurosurgery | |
London, England, United Kingdom, WC1N 3BG |
Study Director: | Medical Director, MD | BioMarin Pharmaceutical |
Responsible Party: | BioMarin Pharmaceutical |
ClinicalTrials.gov Identifier: | NCT03505125 |
Other Study ID Numbers: |
165-901 |
First Posted: | April 23, 2018 Key Record Dates |
Last Update Posted: | January 14, 2020 |
Last Verified: | January 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Phenylketonurias Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Amino Acid Metabolism, Inborn Errors Metabolism, Inborn Errors Genetic Diseases, Inborn Metabolic Diseases |